MyFinsight
Home
Blog
About
Opus Genetics, Inc. (IRD)
Opus Genetics, Inc. (IRD)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$43,821K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Fair value change in instruments...
Proceeds from note purchase agre...
Proceeds from issuance of series...
Others
Negative Cash Flow Breakdown
Net and comprehensive loss
Accounts payable
Issuance costs attributed to not...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Net and comprehensive loss
-73,633
-16,523
-17,454
-15,614
Stock-based compensation
2,871
774
816
1,809
Depreciation
27
13
13
27
Fair value change in instruments measured at fair value, net of cash interest paid of 281
-43,909
-5,712
-9,525
3,722
Non-cash interest, related party
143
61
68
-
Non-cash share issuances
-
57
-
-
Issuance costs related to financing activities
1,113
0
0
1,337
Unrealized loss from short-term investments
0
0
0
-2
Acquired in-process research and development
-
0
-
-
Gain in connection with asset acquisition
-
0
-
-
Accounts receivable
-954
-921
-483
-164
Contract assets and unbilled receivables
-755
-194
186
-1,031
Prepaids and other current assets
640
973
-618
918
Accounts payable
-1,412
804
906
-1,703
Accrued expenses
1,236
-873
-946
-1,676
Net cash used in operating activities
-24,677
-9,833
-6,157
-19,263
Cash received in connection with asset acquisition
-
0
-
-
Net cash used in investing activities
0
0
0
0
Proceeds from note purchase agreement
35,000
-
-
-
Proceeds from stock purchase and conversion agreement
5,000
-
-
-
Proceeds from issuance of common stock and pre-funded warrants in connection with the registered direct offering
-
22,999
-
-
Proceeds from issuance of series b preferred stock
25,000
-
-
-
Issuance costs attributed to equity instruments
-
98
696
1,507
Proceeds from issuance of common stock and pre-funded warrants in connection with the march 2025 offering and march 2025 private placement
0
0
0
5,980
Proceeds from funding agreement, related party
-
0
0
1,000
Proceeds from issuance of warrants in connection with the march 2025 offering and march 2025 private placement
0
0
0
15,520
Proceeds from issuance of common stock in connection with the at-the-market program and purchase agreement
2,250
179
5,217
409
Payments of stock issuance costs
491
-
-
-
Issuance costs attributed to note purchase agreement
1,113
-
-
-
Proceeds from funding agreement, related party
0
-
-
-
Proceeds from warrant exercises
1,663
820
-
-
Exercise of stock options
1,222
325
22
5
Share repurchases for the payment of employee taxes
33
116
0
36
Net cash provided by financing activities
68,498
24,109
4,543
21,371
Net increase (decrease) in cash and cash equivalents
-
14,276
-1,614
2,108
Net increase in cash, cash equivalents and restricted cash
43,821
-
-
-
Cash, cash equivalents and restricted cash at beginning of period
45,091
30,815
30,321
-
Cash, cash equivalents and restricted cash at end of period
88,912
45,091
30,815
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from note
purchase agreement
$35,000K
Proceeds from issuance of
series b preferred...
$25,000K
Proceeds from stock
purchase and conversion...
$5,000K
Proceeds from issuance of
common stock in...
$2,250K
(450.12%↑ Y/Y)
Proceeds from warrant
exercises
$1,663K
Exercise of stock options
$1,222K
(24340.00%↑ Y/Y)
Net cash provided by
financing activities
$68,498K
(220.52%↑ Y/Y)
Canceled cashflow
$1,637K
Net increase in
cash, cash...
$43,821K
Canceled cashflow
$24,677K
Issuance costs
attributed to note purchase...
$1,113K
Payments of stock
issuance costs
$491K
Share repurchases for
the payment of...
$33K
(-8.33%↓ Y/Y)
Fair value change in
instruments measured at fair...
-$43,909K
(-1279.72%↓ Y/Y)
Stock-based compensation
$2,871K
(58.71%↑ Y/Y)
Accrued expenses
$1,236K
(173.75%↑ Y/Y)
Issuance costs related to
financing activities
$1,113K
(-16.75%↓ Y/Y)
Accounts receivable
-$954K
(-481.71%↓ Y/Y)
Contract assets and
unbilled receivables
-$755K
(26.77%↑ Y/Y)
Non-cash interest,
related party
$143K
Depreciation
$27K
(0.00%↑ Y/Y)
Net cash used in
operating activities
-$24,677K
(-28.11%↓ Y/Y)
Canceled cashflow
$51,008K
Net and
comprehensive loss
-$73,633K
(-371.58%↓ Y/Y)
Accounts payable
-$1,412K
(17.09%↑ Y/Y)
Prepaids and other
current assets
$640K
(-30.28%↓ Y/Y)
Buy us a coffee